All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
The FDA grants acalabrutinib Breakthrough Therapy Designation for relapsed/refractory Mantle Cell Lymphoma
On 1st August 2017, acalabrutinib was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Mantle Cell Lymphoma (MCL) who have received one or more previous therapies.
AstraZeneca’s acalabrutinib is an oral, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor and prevents activation of the B-Cell Receptor (BCR) signaling pathway.
The BTD is based on data from the acalabrutinib development program investigating monotherapy and combination regimens in a wide range of solid and hematological tumors; and includes data from the ACE-LY-004 trial (NCT02213926). This is a phase II, open-label study aiming to determine the safety and efficacy of acalabrutinib in patients with Relapsed/Refractory (R/R) MCL. This trial is estimated to complete in January 2018 and has an estimated enrolment of 124 patients. The primary endpoint is Overall Response Rate (ORR).
Trials currently recruiting patients investigating acalabrutinib include a phase III trial of bendamustine and rituximab alone or in combination with acalabrutinib in newly diagnosed MCL (NCT02972840), a phase II study of acalabrutinib in R/R Chronic Lymphocytic Leukemia (CLL) and newly diagnosed del(17p) CLL (NCT02337829), and a broader phase I/II trial of acalabrutinib combined with the PI3K inhibitor ACP-319 in B-cell malignancies (NCT02328014).
References